Skip to main content

Radiation Dermatitis

Dermatology
1
Pipeline Programs
4
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 5 programs with unclassified modality

Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.

$0.292B marketMature→ Stable30 products15 companies

Key Trends

  • HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
  • Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
  • Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market

Career Verdict

Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING
#2VTAMAGrowing
$19M
Merck & Co.·PEAK13.5yr
#3ORACEADeclining
$4M
Galderma·LOE_APPROACHING1.6yr

Drug Class Breakdown

Unknown Mechanism (predominantly HUMIRA)
$258M(88%)

Patent cliff looming

Aryl Hydrocarbon Receptor Agonists
$19M(6%)

Emerging innovation

Retinoids and Derivatives
$3M(1%)

Mature segment

Other Mechanisms
$12M(4%)

Niche applications

Career Outlook

Stable

Dermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.

Breaking In

Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.

For Experienced Professionals

Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.

In-Demand Skills

Health Economics & Outcomes Research (HEOR)Dermatology Clinical KnowledgeSales Strategy & Account ManagementDigital Health / Telemedicine IntegrationMedical Writing for Topicals & Systemics

Best For

Regional Sales ManagerMedical Science Liaison (MSL)Product Manager (Post-Launch)Health Economics ManagerRegulatory Affairs Specialist

Hiring Landscape

$85K-$386K

Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.

173
Open Roles
3
Companies Hiring
3
Departments

Top Hiring Companies

53Growing
46Growing
14Stable

By Department

Commercial(51%)
$188K
Medical Affairs(24%)
$386K
Research & Development(5%)

Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Lutris Pharma
Lutris PharmaIsrael - Tel Aviv
1 program
1
LUT014 GelPhase 1/21 trial
Active Trials
NCT04261387Completed28Est. Jul 2022
Stratpharma
StratpharmaSwitzerland - Basel
3 programs
StrataXRTN/A1 trial
StrataXRTN/A1 trial
StrataXRTN/A1 trial
Active Trials
NCT05553392Terminated13Est. May 2024
NCT05450848Completed105Est. Mar 2023
NCT05810194Completed344Est. Dec 2023
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
GelronateN/A1 trial
Active Trials
NCT03941665Completed136Est. May 2020
KeraNetics
KeraNeticsNC - Winston-Salem
1 program
KeraStatN/ASmall Molecule1 trial
Active Trials
NCT03559218Completed25Est. Nov 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lutris PharmaLUT014 Gel
StratpharmaStrataXRT
StratpharmaStrataXRT
Ferring PharmaceuticalsGelronate
KeraNeticsKeraStat
StratpharmaStrataXRT

Clinical Trials (6)

Total enrollment: 651 patients across 6 trials

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

Start: Jan 2021Est. completion: Jul 202228 patients
Phase 1/2Completed

Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis

Start: May 2023Est. completion: Dec 2023344 patients
N/ACompleted

StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis

Start: Nov 2022Est. completion: May 202413 patients
N/ATerminated

Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients

Start: Mar 2019Est. completion: May 2020136 patients
N/ACompleted

KeraStat(R) Cream for Radiation Dermatitis

Start: Apr 2018Est. completion: Nov 201825 patients
N/ACompleted

StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis

Start: Sep 2017Est. completion: Mar 2023105 patients
N/ACompleted

Related Jobs in Dermatology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.